NASDAQ:NXTM - NxStage Medical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$29.30 +0.13 (+0.45 %)
(As of 02/19/2019 09:30 AM ET)
Previous Close$29.17
Today's Range$29.06 - $29.36
52-Week Range$23.17 - $29.36
Volume731,012 shs
Average Volume659,878 shs
Market Capitalization$1.95 billion
P/E Ratio-133.18
Dividend YieldN/A
Beta0.25
NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts.

Receive NXTM News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:NXTM
CUSIP67072V10
Phone978-687-4700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$393.94 million
Cash Flow$0.2924 per share
Book Value$3.22 per share

Profitability

Net Income$-14,470,000.00

Miscellaneous

Employees3,800
Market Cap$1.95 billion
OptionableOptionable

NxStage Medical (NASDAQ:NXTM) Frequently Asked Questions

What is NxStage Medical's stock symbol?

NxStage Medical trades on the NASDAQ under the ticker symbol "NXTM."

How were NxStage Medical's earnings last quarter?

NxStage Medical, Inc. (NASDAQ:NXTM) released its earnings results on Monday, August, 7th. The medical device company reported ($0.03) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.00. The medical device company had revenue of $92.20 million for the quarter, compared to analysts' expectations of $96.47 million. NxStage Medical had a negative return on equity of 2.50% and a negative net margin of 1.29%. The business's quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.03) earnings per share. View NxStage Medical's Earnings History.

Has NxStage Medical been receiving favorable news coverage?

Media stories about NXTM stock have trended positive this week, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NxStage Medical earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave headlines about the medical device company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.

Are investors shorting NxStage Medical?

NxStage Medical saw a increase in short interest in January. As of January 31st, there was short interest totalling 5,295,746 shares, an increase of 40.4% from the January 15th total of 3,770,838 shares. Based on an average daily volume of 797,224 shares, the short-interest ratio is currently 6.6 days. Approximately 8.1% of the shares of the company are sold short. View NxStage Medical's Current Options Chain.

Who are some of NxStage Medical's key competitors?

Who are NxStage Medical's key executives?

NxStage Medical's management team includes the folowing people:
  • Mr. Jeffrey H. Burbank, Founder, CEO & Director (Age 56)
  • Mr. Joseph E. Turk Jr., Pres (Age 51)
  • Mr. Matthew W. Towse, Sr. VP, CFO & Treasurer (Age 56)
  • Ms. Winifred L. Swan, Sr. VP, Gen. Counsel & Sec. (Age 55)
  • Dr. Allan J. Collins, Head of Scientific Advisory Board & Chief Medical Officer

Who are NxStage Medical's major shareholders?

NxStage Medical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.13%), Alpine Associates Management Inc. (3.65%), Millennium Management LLC (2.69%), Citigroup Inc. (1.71%), Manikay Partners LLC (1.69%) and Northern Trust Corp (1.26%). Company insiders that own NxStage Medical stock include Craig W Moore, Jeffrey H Burbank, Joseph E Turk Jr, Matthew W Towse, Robert S Brown and Winifred L Swan. View Institutional Ownership Trends for NxStage Medical.

Which major investors are selling NxStage Medical stock?

NXTM stock was sold by a variety of institutional investors in the last quarter, including Water Island Capital LLC, Alpine Associates Management Inc., Flossbach Von Storch AG, SG Americas Securities LLC, Bank of New York Mellon Corp, Barclays PLC, D. E. Shaw & Co. Inc. and California State Teachers Retirement System. View Insider Buying and Selling for NxStage Medical.

Which major investors are buying NxStage Medical stock?

NXTM stock was acquired by a variety of institutional investors in the last quarter, including Manikay Partners LLC, Millennium Management LLC, LMR Partners LLP, Canada Pension Plan Investment Board, Hsbc Holdings PLC, BlackRock Inc., TT International and Citigroup Inc.. View Insider Buying and Selling for NxStage Medical.

How do I buy shares of NxStage Medical?

Shares of NXTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NxStage Medical's stock price today?

One share of NXTM stock can currently be purchased for approximately $29.30.

How big of a company is NxStage Medical?

NxStage Medical has a market capitalization of $1.95 billion and generates $393.94 million in revenue each year. The medical device company earns $-14,470,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. NxStage Medical employs 3,800 workers across the globe.

What is NxStage Medical's official website?

The official website for NxStage Medical is http://www.nxstage.com.

How can I contact NxStage Medical?

NxStage Medical's mailing address is 350 MERRIMACK STREET, LAWRENCE MA, 01843. The medical device company can be reached via phone at 978-687-4700 or via email at [email protected]


MarketBeat Community Rating for NxStage Medical (NASDAQ NXTM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  324 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  597
MarketBeat's community ratings are surveys of what our community members think about NxStage Medical and other stocks. Vote "Outperform" if you believe NXTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel